IP Library Granted Patent US 7,955,598
Granted Patent B2
US 7,955,598 · App. 11/704,233 · Granted Jun 7, 2011

Therapeutic agent for chronic arthritides diseases of childhood-related diseases

Assignee: Chugai Seiyaku Kabushiki Kaisha
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,955,598
App. No.
11/704,233
Granted
Jun 7, 2011
Kind
B2
Abstract

A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims (9)

1. A method for treatment of adult-onset Still's disease, comprising administering an antibody against an IL-6 receptor to a patient who needs said treatment, wherein the antibody against the IL-6 receptor is an antibody which inhibits binding of IL-6 to the IL-6 receptor by binding to the IL-6 receptor.

2. A method according to claim 1 , wherein the antibody against the IL-6 receptor is a monoclonal antibody.

3. A method according to claim 2 , wherein the monoclonal antibody is a monoclonal antibody against the human IL-6 receptor.

4. A method according to claim 1 , wherein the antibody against the IL-6 receptor is a recombinant antibody.

5. A method according to claim 3 , wherein the monoclonal antibody against the human IL-6 receptor is the PM-1 antibody (FERM BP-2998) or a humanized or chimeric version thereof.

6. A method according to claim 1 , wherein the antibody against a IL-6 receptor is a chimeric antibody, humanized antibody or a human antibody.

7. A method according to claim 6 , wherein the humanized antibody is a humanized variant of PM-1 antibody (FERM BP-2998).

8. A method according to claim 1 , wherein the antibody is administered to the patient at a dose of 0.5 to 40 mg per kilogram of body weight every four weeks.

9. A method according to claim 7 , wherein the antibody is administered to the patient at a dose of 0.5 to 40 mg per kilogram of body weight every four weeks.

Priority Claims (2)
JP 2001-103627 · Apr 2, 2001 · national
JP 2001-109131 · Apr 6, 2001 · national
Continuity (2)
Division 10473165
Related Publication 20070148169A1 · Jun 28, 2007